Breast cancer recurrent

5 trials 1 recruiting MedDRA PT
5 Registered trials
1 Recruiting
5 Unique sponsors
9 Unique IMPs
2 Commercial trials
Drug classes (ATC)
L Oncology (ATC L) 3
— ATC code not specified 2
Mechanism of action (INN-stem analysis)
Platinum compound 2 substances
Taxane 1 substance
Unknown / small molecule 1 substance
CDK inhibitor 1 substance
Antimetabolite 1 substance
Antibody-drug conjugate (ADC) 1 substance
Checkpoint inhibitor (PD-L1) 1 substance
Monoclonal antibody 1 substance
Phase III: 2 Phase II/III: 1 Phase I/II: 1 Phase I (First in Human): 1

Filter these 5 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 5 trials

Phase III

2 trials
  • ETOP IBCSG Partners Foundation Academic
    PALBOCICLIB
    2024-510776-20-00 5 countries 2019 n=381
    Ended
  • GBG Forschungs GmbH Academic
    CAPECITABINE; CARBOPLATIN; CISPLATIN; SACITUZUMAB GOVITECAN
    2023-510390-33-00 6 countries 2020 n=1,386
    Ended

Phase II/III

1 trial
  • Daehwa Pharmaceutical Co. Ltd. Commercial
    PACLITAXEL
    2024-517090-24-00 1 country 2020 n=10
    Ended

Phase I/II

1 trial
  • Institut Jules Bordet Academic
    DURVALUMAB; OLECLUMAB
    2024-511850-34-00 2 countries 2019 n=209
    Ended

Phase I (First in Human)

1 trial
  • Daiichi Sankyo Inc. Commercial
    DS-3939A
    2023-507937-14-00 3 countries 2025 n=207
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Daehwa Pharmaceutical Co. Ltd. Commercial 1 Phase II/III 0
Daiichi Sankyo Inc. Commercial 1 Phase I (First in Human) 1
ETOP IBCSG Partners Foundation Academic 1 Phase III 0
GBG Forschungs GmbH Academic 1 Phase III 0
Institut Jules Bordet Academic 1 Phase I/II 0
New trials by year
2019
2
2020
2
2025
1
← All indication landscapes